229639-54-7

Usage

Uses

Used in Pharmaceutical Research:
(R)-(+)-N-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl-N-methylamine is used as a research compound for its potential biological activity and its ability to interact with various biological targets. Its unique structure and chirality make it a valuable tool in the development of new drugs and therapies.
Used in Drug Development:
In the pharmaceutical industry, (R)-(+)-N-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl-N-methylamine is used as a lead compound for the development of new medications. Its interaction with biological targets can be exploited to create drugs that target specific receptors or enzymes, potentially leading to more effective treatments for various diseases and conditions.
Used in Chemical Synthesis:
(R)-(+)-N-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl-N-methylamine can also be used as a building block or intermediate in the synthesis of more complex molecules. Its unique structural features can be incorporated into other compounds, potentially leading to the creation of new materials with novel properties and applications.

Upstream product

• 920-36-5 (2-methylpropyl)lithium 
• 259729-89-0 [1-[1-(4-Chloro-phenyl)-cyclobutyl]-meth-(E)-ylidene]-methyl-amine 
• 352-33-0 1-Chloro-4-fluorobenzene 
• 106650-56-0 sibutramine 
• 106079-12-3 1-(4-chlorophenyl)-cyclobutanecarboxaldehyde 
• 4426-11-3 cyclobutanecarbonitrile 
• 154752-44-0 (R)-(+)-N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine 
• 28049-61-8 1-(4-chlorophenyl)cyclobutanecarbonitrile 

Downstream Products

• 154752-44-0 (R)-(+)-N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine 

Relevant academic research and scientific papers

First asymmetric synthesis of (R)-desmethylsibutramine

A catalytic enantioselective addition of iBuLi to aldimine 3 derived from methyl amine and 1-(4-chlorophenyl) cyclobutanecarboxaldehyde is used as the key step in the asymmetric synthesis of (R)-desmethylsibutramine, a single enantiomer version of a pharmacologically active metabolite of anti-obesity drug sibutramine (Meridia).

First preparation of enantiomerically pure sibutramine and its major metabolite, and determination of their absolute configuration by single crystal X-ray analysis

Racemic sibutramine was resolved with dibenzoyl-D-tartaric acid, and the absolute stereochemistry of sibutramine was determined by single crystal X- ray crystallography of its dibenzoyl D-tartrate. The major active metabolite (desmethylsibutramine) was ob

ENANTIOSELECTIVE SYNTHESIS OF A STERICALLY HINDERED AMINE

Compounds of the formula (I) wherein R is phenyl, or phenyl substituted by Cl, Br, C1-C4alkyl or CF3; R1 is H or methyl or ethyl; R2 is H or methyl or acyl; R3 is H or methyl; R'4/sub

Therapeutic agents

The present invention provides a method of treating and preventing obesity and related co-morbid conditions comprising the administration of a therapeutically effective amount of one or more monoamine reuptake inhibitors which are serotonin reuptake inhibitors and/or noradrenaline reuptake inhibitors and a 5-HT1A agonist to a patient in need thereof.